Dr. Reddy's Laboratories Ltd.’ Announces The Launch Of Eszopiclone Tablets C-IV

HYDERABAD, India--(BUSINESS WIRE)--Dr. Reddy’s Laboratories (NYSE: RDY) announced today that it has launched Eszopiclone Tablets (C-IV) 1 mg, 2 mg and 3 mg, a therapeutic equivalent generic version of LUNESTA® (eszopiclone) tablets C-IV in the US market on April 15, 2014, following the approval by the United States Food & Drug Administration (USFDA).

Help employers find you! Check out all the jobs and post your resume.